Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications
Combining Systemic and Local/Regional Approaches to Improve Immunotherapy Sensitivity.
Journal: Surgical oncology clinics of North America
Published: March 28, 2026
Neoadjuvant Immune Therapy in Patients With Melanoma: Response and Toxicity in a Non-Clinical Trial Setting.
Journal: Journal of surgical oncology
Published: February 18, 2026
Biosynthetic Versus Synthetic Mesh in Oncologic Ventral Hernia Repair.
Journal: Plastic and reconstructive surgery
Published: January 28, 2026
RP-1 Fires Up Tumors but Fails to Get FDA Approval.
Journal: Annals of surgical oncology
Published: October 21, 2025
Outcomes of Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma.
Journal: Annals of surgical oncology
Published: August 25, 2025
Local Recurrence Following Complete Surgical Excision of Primary Merkel Cell Carcinoma.
Journal: Annals of surgical oncology
Published: August 21, 2025
Melanoma Great Debate: Targeted Versus Complete Nodal Dissection Following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold Off on Continued De-Escalation of Surgery?
Journal: Annals of surgical oncology
Published: July 25, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 10, 2025
Clinical outcomes of oncologic hernia repair using Poly-4-Hydroxybutyrate (P4HB) mesh.
Journal: Hernia : the journal of hernias and abdominal wall surgery
Published: June 16, 2025
Malignant CRTC1::TRIM11 Cutaneous Tumor With Lethal Outcome: Histopathologic and Molecular Findings.
Malignant CRTC1::TRIM11 Cutaneous Tumor With Lethal Outcome: Histopathologic and Molecular Findings.
Journal: Journal of cutaneous pathology
Published: March 20, 2025
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer.
Journal: Cancer cell
Published: October 10, 2024
Last Updated: 09/26/2026